Last November, a physical therapist named Marcus in Austin texted his prescriber a photo of his insulin syringe next to a freshly reconstituted 10 mg vial of BPC-157. "I keep getting 250 on the math but it looks like nothing in the barrel. Am I doing this right?" His prescriber confirmed: yes, 50 units on a 100-unit insulin syringe, assuming 2 mL of bacteriostatic water. It really is that small of an injection. Marcus ran a four-week protocol for a partial supraspinatus tear, 500 mcg twice daily for the first two weeks, then tapered. He described the improvement as "noticeable but not miraculous," which is about the most honest summary you'll hear from anyone paying attention.
That kind of dosing, 250 to 500 mcg per day subcutaneously, run in 4- to 8-week blocks, is the working baseline across published research and clinical reports. Everything else (oral routes, higher loading doses, longer cycles) gets layered on top of that anchor based on a prescriber's clinical judgment and the patient's specific goal.
BPC-157 is a research peptide. It is not FDA-approved. It is prepared by licensed compounding pharmacies when a licensed prescriber decides the use case fits the patient. The dosing ranges in this article come from published research and reported clinical practice, not a recommendation to self-administer.
The 250-500 mcg Subcutaneous Standard
The most frequently referenced human protocol, drawn from the Sikiric P et al. research group's decades of animal work and adjusted by allometric scaling, looks like this:
- 250 mcg once daily, or
- 250 mcg twice daily (totaling 500 mcg/day)
Some clinicians push to 500 mcg twice daily (1,000 mcg/day) for acute orthopedic injuries, then taper back once the worst inflammation window closes. The peptide is small and water-soluble, making subcutaneous absorption reliably consistent. Injection near the site of injury became popular in tendon and joint protocols, though Sikiric's animal data actually suggest systemic benefit even when the injection site is nowhere near the target tissue. Think of it less like applying a topical cream and more like dropping a message into the bloodstream.
The Oral Route: Useful or Wishful?
Here's the thing about oral BPC-157: it shouldn't work systemically, and yet it might work locally, and that distinction matters enormously depending on what you're trying to accomplish.
The pro-oral argument leans on Sikiric's rat studies showing oral administration still produced effects on gut and systemic targets, suggesting either direct local gut activity or some intact peptide survival through the GI tract. The skeptical argument is straightforward: a 15-amino-acid peptide should get chewed apart by gastric and pancreatic proteases, so the systemic dose actually reaching circulation is anyone's guess.
For gut-specific goals (gastritis, IBD-like symptoms, ulcer recovery), oral makes real mechanistic sense because the target tissue is literally in the GI tract. The peptide can do its work before digestion destroys it. For tendon, joint, or neurological targets, injectable is the more defensible route.
Oral doses typically run higher to compensate for assumed degradation: 500 mcg to 1,000 mcg per day, delivered via capsules or liquid oral suspensions.
My honest take: if someone is paying compounding pharmacy prices for BPC-157 and targeting a knee tendon, choosing the oral route feels like lighting money on fire. Save oral for gut applications.
Loading and Tapering: One Option, Not a Rule
Some protocols front-load the first 1 to 2 weeks at a higher dose, then step down:
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →- Loading: 500 mcg twice daily for 14 days
- Maintenance: 250 mcg once daily for the remainder of the cycle
The rationale is faster tissue saturation during the acute injury window. There is no controlled human data confirming that loading outperforms a flat dose. Treat it as one tool in the toolbox.
Two Sample Protocols
4-Week Acute Soft-Tissue Injury Protocol
| Week | Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| 1 | 500 mcg | Twice daily | SubQ | Load phase, near injury site |
| 2 | 500 mcg | Twice daily | SubQ | Continue load |
| 3 | 250 mcg | Twice daily | SubQ | Taper |
| 4 | 250 mcg | Once daily | SubQ | Maintenance |
Then off-cycle 4 to 8 weeks and reassess.
8-Week Chronic Gut or Joint Protocol
| Week | Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| 1-2 | 250 mcg | Twice daily | SubQ or oral | Establish baseline |
| 3-6 | 250 mcg | Once daily | SubQ or oral | Steady state |
| 7-8 | 250 mcg | Once daily | SubQ or oral | Optional taper |
The longer format is more common when the condition is chronic and a slower onset is expected.
Reconstitution Math (the Part People Get Wrong)
A typical BPC-157 vial from a compounding pharmacy contains 5 mg or 10 mg of lyophilized powder. Reconstitution converts that powder into an injectable liquid using bacteriostatic water.
Here's the step-by-step for a 10 mg vial:
- Draw 2 mL of bacteriostatic water into a syringe.
- Inject slowly down the inside wall of the vial. Do not shake. Swirl gently until dissolved.
- The vial now holds 10 mg in 2 mL = 5,000 mcg per mL = 5 mcg per unit on a 100-unit insulin syringe (because 100 units = 1 mL).
To draw 250 mcg, pull to the 50-unit mark. To draw 500 mcg, pull to 100 units (the full 1 mL mark).
If you reconstitute that same 10 mg vial with only 1 mL of bacteriostatic water:
- Concentration doubles to 10 mg per mL, or 10 mcg per unit.
- 250 mcg = 25 units on the syringe.
- 500 mcg = 50 units on the syringe.
Lower reconstitution volume means smaller injection volume, which some people prefer for comfort. The math just has to be recalculated every time the dilution changes. Write it on a piece of tape stuck to the vial. Seriously. Do not try to remember it.
Cycling: Why You Don't Run This Continuously
Most prescribers who use BPC-157 cycle it. Continuous-use safety data in humans is essentially nonexistent. Common structures:
- 4 weeks on, 4 weeks off
- 8 weeks on, 4 to 8 weeks off
- 12 weeks on, 12 weeks off (more aggressive, used in some chronic protocols)
The off-cycle period exists as a precaution against unknown long-term effects, particularly around angiogenesis. That's one of BPC-157's proposed wound-healing mechanisms, and it's also the same biological process that feeds tumor growth. No published evidence connects BPC-157 to cancer. But the theoretical overlap is exactly why cycling became standard practice. It's the cheapest insurance policy in the protocol.
Injection Sites and Rotation
Subcutaneous sites that work well for BPC-157:
- Abdomen, roughly two inches lateral from the navel, alternating left and right
- Outer thigh
- Upper arm fat pad (less common)
- Adjacent to injured tissue (the peri-lesional approach popular in tendon protocols)
Rotate daily to reduce localized irritation. The peptide distributes systemically regardless of site, so the peri-lesional argument is more about practitioner preference than confirmed pharmacokinetics.
The Mistakes That Actually Cost People
- Mixing up mg and mcg. A 10 mg vial holds 10,000 mcg. Getting the unit wrong by a factor of 1,000 is not a rounding error.
- Reusing syringes or needles. Single-use. Every time.
- Leaving reconstituted vials at room temperature. Refrigerate after mixing. Most compounded vials are stable for about 30 days refrigerated; check your label.
- Injecting intramuscularly when the protocol calls for subcutaneous. IM is not the standard route here.
- Running BPC-157 continuously for 6+ months without an off-period. This removes one of the only safety hedges the entire protocol has.
Storage After Reconstitution
- Refrigerate at 36-46°F.
- Keep vial upright.
- Do not freeze.
- Discard at the date on the compounding pharmacy label, typically 28 to 30 days after reconstitution.
- If the solution turns cloudy or changes color, discard it. No exceptions.
When to Adjust the Dose
Scale down if you notice:
- Injection-site reactions persisting beyond 48 hours
- Persistent headache or dizziness
- Any unexplained new symptom
Scale up (within the published range) only under prescriber direction, typically when four weeks at 250 mcg/day has produced no measurable change in the target outcome. "More" is not a substitute for "different approach."
Internal Links
- BPC-157 hub page
- Peptide protocols overview
- BPC-157 side effects explained
- BPC-157 how to inject step-by-step
- BPC-157 cycling protocols
FAQ
What is the most common BPC-157 dose? 250 mcg once or twice daily subcutaneously is the most frequently cited range in protocols derived from the Sikiric research line.
Can BPC-157 be taken orally? Some practitioners use oral BPC-157 for gut-specific issues. Injectable has more research support for systemic targets. Oral doses are typically higher to account for assumed degradation.
How long does a reconstituted vial last? Most compounded BPC-157 is labeled stable for 28 to 30 days refrigerated after reconstitution. Follow the pharmacy label.
Do I need to inject near the injury? Animal data shows systemic effect regardless of injection site. Some protocols still use peri-lesional injection for orthopedic targets based on practitioner preference.
What happens if I miss a dose? Skip it and take the next scheduled dose. Do not double up. The peptide has a short half-life, so a single missed dose is unlikely to derail a cycle.
Is there a maximum safe dose of BPC-157? There is no formally established maximum in humans. The upper end seen in clinical reports is around 1,000 mcg/day. Anything beyond that lacks even anecdotal support and should only be considered with direct prescriber oversight.
Disclaimer
BPC-157 is a research peptide. It is not FDA-approved for any indication. The information above reflects published research and reported clinical practice and is not a prescription or medical advice. Compounded BPC-157 is dispensed only when a licensed prescriber determines, in clinical judgment, that it is appropriate for the patient. Individual results vary. Do not self-administer without prescriber guidance.